Ypsilon Receives CPRIT Grant to Accelerate Antibody Therapeutic
Ypsilon Therapeutics, part of Alloy’s venture studio 82VS, has received seed funding from CPRIT. The funding will accelerate its lead program—a next-generation T-cell receptor mimic (TCRm) antibody—toward drug candidate nomination, aiming to provide breakthrough treatments for hard-to-treat solid tumors like triple-negative breast cancer, non-small cell lung cancer, and gastric cancer. This grant will also help establish Ypsilon’s operations in Texas.
Ypsilon Receives CPRIT Grant to Accelerate Antibody Therapeutic